February 24, 2025
2 min watch
Save
VIDEO: Promising immune therapies for CLL among highlights from ASH
SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.
Highlights from Woyach, professor in the division of hematology at The Ohio State University, include a study that evaluated epcoritamab (Epkinly; Genmab, AbbVie) monotherapy, and another that looked at lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) — also called liso-cel — combined with ibrutinib (Imbruvica, Janssen/Pharmacyclics) for patients with relapsed or refractory CLL.
References:
- Danilov A, et al. Abstract 883. Presented at: ASH Annual Meeting and Exhibition; Dec. 7-10, 2024; San Diego.
- Wierda WG, et al. Abstract 887. Presented at: ASH Annual Meeting and Exhibition; Dec. 7-10, 2024; San Diego.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Woyach reports serving in consulting roles for AstraZeneca, AbbVie, Genentech, Janssen, Loxo Lilly, Merck, Newave Pharmaceutical, Pharmacyclics and Schrödinger.
Read more about